Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEG35156 with Chemotherapy in Refractory AML
NCT01018069Phase 2Terminated
- Sponsor
- Aegera Therapeutics
- Start
- Nov 2009
- Primary completion
- Oct 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 3
01
Overview
A Phase 2 trial of AEG35156 in acute myeloid leukemia (AML), sponsored by Aegera Therapeutics. Started Nov 2009; status: terminated.
02
Drugs
AEG35156
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01018069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01018069.